miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism

Chondrosarcoma is the second most common type of primary bone malignancy in the United States after osteosarcoma. Surgical resections of these tumors are the only effective treatment to chondrosarcoma patients due to their resistance to conventional chemo- and radiotherapy. In this study, miR-125b w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xian-ye, Zheng, Wei, Ding, Min, Guo, Kai-jin, Yuan, Feng, Feng, Hu, Deng, Bin, Sun, Wei, Hou, Yang, Gao, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771406/
https://www.ncbi.nlm.nih.gov/pubmed/26966351
http://dx.doi.org/10.2147/DDDT.S90530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771406/
https://www.ncbi.nlm.nih.gov/pubmed/26966351
http://dx.doi.org/10.2147/DDDT.S90530

Ejemplares similares